CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Registration Number
- NCT03163667
- Lead Sponsor
- Calithera Biosciences, Inc
- Brief Summary
The primary objective of this study is to compare the progression-free survival (PFS) of participants treated with telaglenastat and everolimus versus placebo and everolimus for advanced or metastatic clear cell renal cell carcinoma (ccRCC) previously treated with the following:
* At least 2 lines of therapy, including at least 1 vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)
* Radiographic progression of metastatic RCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to cycle 1 day 1
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 69
-
Karnofsky Performance Score (KPS) ≥ 70%
-
Estimated Life Expectancy of at least 3 months
-
Documented histological or cytological diagnosis of renal cell carcinoma with a clear-cell component.
-
Measurable Disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the Investigator
-
Must have received at least two prior lines of systemic therapy, including at least one VEGF TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib)
a) Radiographic progression of mRCC must have occurred (per investigator assessment) on or after the most recent systemic therapy and within 6 months prior to Cycle 1 Day 1 (C1D1).
-
Prior treatment with other anti-cancer therapies including cytokines, monoclonal antibodies, immunotherapies, and cytotoxic chemotherapy is allowed
-
Prior treatment with mammalian target of rapamycin (mTOR) inhibitors (everolimus or temsirolimus) or CB-839
-
Receipt of any anticancer therapy within the following windows before randomization:
- TKI therapy within 2 weeks or 5 half-lives, whichever is longer
- Any type of anti-cancer antibody within 4 weeks
- Cytotoxic chemotherapy within 4 weeks
- Investigational therapy within 4 weeks or 5 half-lives, whichever is longer
- Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Patients with clinically relevant ongoing complications from prior radiation therapy are not eligible.
-
Unable to receive medications orally (PO) or any condition that may prevent adequate absorption of oral study medication
-
Major surgery within 28 days prior to randomization
-
Patients with active and/or untreated central nervous system (CNS) cancer are not eligible. Patients with treated brain metastasis must have 1) documented radiographic stability of at least 4 weeks duration demonstrated on baseline contrast-enhanced CNS imaging (eg contrast-enhanced magnetic resonance imaging [MRI] of the brain) prior to randomization and 2) must be symptomatically stable and off steroids for at least 2 weeks before randomization.
-
Requirement for continued proton pump inhibitor after randomization
-
Chronic treatment with corticosteroids or other immunosuppressive agents except (i) inhaled or topical steroids or replacement dose corticosteroids equivalent to ≤ 10 mg prednisone and (ii) patients receiving physiological doses of hydrocortisone for adrenal insufficiency
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description CB-839 + Everolimus CB-839 CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles. Placebo + Everolimus Placebo Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles. CB-839 + Everolimus everolimus CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles. Placebo + Everolimus everolimus Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) As of the primary data cutoff date of 26 Apr 2019; maximum duration of follow-up for PFS was 11.2 months. PFS was defined as the time from randomization to the date of documented disease progression (assessed by Investigator per Response Evaluation Criteria in Solid Tumors \[RECIST\] v1.1) within 2 scheduled scan intervals following previous evaluable radiologic tumor assessment or death for any cause, whichever occurred first. Participants with no documentation of disease progression or death on-study were censored at the date of last available tumor assessment.
Progressive Disease (PD) per RECIST 1.1: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) As of the data cutoff date of 30 Sep 2020; maximum duration of follow-up for OS was 30.4 months. Overall survival is defined as the time from randomization to the date of death from any cause. Participants with no documentation of death on-study were censored at the date at which they were last known to be alive.
Trial Locations
- Locations (38)
Stanford Cancer Center
🇺🇸Stanford, California, United States
University Cancer & Blood Center, LLC
🇺🇸Athens, Georgia, United States
Florida Cancer Specialists- North
🇺🇸Saint Petersburg, Florida, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Norton Cancer Institute, Norton Healthcare Pavilion
🇺🇸Louisville, Kentucky, United States
Anne Arundel Medical Center Oncology and Hematology
🇺🇸Annapolis, Maryland, United States
SCRI HCA Midwest
🇺🇸Kansas City, Missouri, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
North Shore Hematology Oncology Associates PC DBA NY Cancer and Blood Specialists
🇺🇸East Setauket, New York, United States
Ann B. Barshinger Cancer Institute / Lancaster General Hospital
🇺🇸Lancaster, Pennsylvania, United States
Monongahela Valley Hospital
🇺🇸Monongahela, Pennsylvania, United States
Los Angeles Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
UCLA Department of Medicine - Hematology/Oncology
🇺🇸Los Angeles, California, United States
Northwest Georgia Oncology Centers, P.C.
🇺🇸Marietta, Georgia, United States
Northwestern University
🇺🇸Chicago, Illinois, United States
Parkview Research Center
🇺🇸Fort Wayne, Indiana, United States
Mercy Clinic Oncology & Hematology
🇺🇸Joplin, Missouri, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Wenatchee Valley Hospital and Clinics
🇺🇸Wenatchee, Washington, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
University of Cincinnati Medical Center
🇺🇸Cincinnati, Ohio, United States
Metro-Minnesota Community Oncology Research Consortium
🇺🇸Saint Louis Park, Minnesota, United States
Sarah Cannon Research Institute - Tennessee Oncology
🇺🇸Nashville, Tennessee, United States
Utah Cancer Specialists
🇺🇸Salt Lake City, Utah, United States
Florida Cancer Specialists- South
🇺🇸Fort Myers, Florida, United States
University of Maryland, Greenebaum Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Highlands Oncology Group
🇺🇸Rogers, Arkansas, United States
St. Luke's Mountain States Tumor Institute
🇺🇸Boise, Idaho, United States
Charleston Hematology Oncology Associates,PA
🇺🇸Charleston, South Carolina, United States
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
University of Wisconsin Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
UT/Erlanger Oncology & Hematology
🇺🇸Chattanooga, Tennessee, United States
The University of Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
Ochsner Clinical Foundation
🇺🇸New Orleans, Louisiana, United States
NYU Winthrop Hospital - Cancer Clinical Trials Oncology/Hematology
🇺🇸Mineola, New York, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States